ProMIS Neurosciences, Inc. (PMN)
PMN Stock Price Chart
Explore ProMIS Neurosciences, Inc. interactive price chart. Choose custom timeframes to analyze PMN price movements and trends.
PMN Company Profile
Discover essential business fundamentals and corporate details for ProMIS Neurosciences, Inc. (PMN) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
10 Jan 2007
Employees
7.00
CEO
Neil K. Warma
Description
ProMIS Neurosciences, Inc. is a Canadian biotechnology firm dedicated to creating targeted therapeutic solutions for debilitating neurodegenerative conditions such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company leverages a unique computational discovery platform, utilizing its ProMIS and Collective Coordinates algorithms, to identify novel, disease-specific targets – known as epitopes – located on the surface of misfolded proteins. Its pipeline features several promising drug candidates, including PMN310, a monoclonal antibody designed to address toxic oligomers implicated in Alzheimer's disease. Another candidate, PMN267, targets superoxide dismutase 1 and TAR-DNA binding protein 43 in ALS, and alpha-synuclein associated with Parkinson's disease and Lewy body dementia. Finally, PMN442 is a monoclonal antibody aimed at toxic alpha-synuclein oligomers and seeding fibrils relevant to multiple system atrophy. Established in 2004, the company changed its name from Amorfix Life Sciences Ltd. to ProMIS Neurosciences, Inc. in July 2015. Its corporate headquarters are situated in Toronto, Canada.
PMN Financial Timeline
Browse a chronological timeline of ProMIS Neurosciences, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 12 Aug 2026
EPS estimate is -$1.45.
Earnings released on 12 May 2026
EPS came in at -$1.26 falling short of the estimated -$1.06 by -18.87%.
Earnings released on 25 Mar 2026
EPS came in at -$4.11 surpassing the estimated -$4.66 by +11.80%.
Stock split effective on 28 Nov 2025
Shares were split 1 : 25 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 12 Nov 2025
EPS came in at -$6.00 falling short of the estimated -$3.75 by -60.00%.
Earnings released on 13 Aug 2025
EPS came in at -$0.29 falling short of the estimated -$0.22 by -31.82%.
Earnings released on 12 May 2025
EPS came in at -$0.21 falling short of the estimated -$0.12 by -75.00%.
Earnings released on 31 Mar 2025
EPS came in at -$0.02 surpassing the estimated -$0.14 by +85.71%.
Earnings released on 14 Nov 2024
EPS came in at -$0.14 falling short of the estimated -$0.07 by -100.00%.
Earnings released on 8 Aug 2024
EPS came in at -$0.13 surpassing the estimated -$0.14 by +7.14%.
Earnings released on 14 May 2024
EPS came in at -$0.19 surpassing the estimated -$0.20 by +5.00%.
Earnings released on 1 Apr 2024
EPS came in at -$0.09 surpassing the estimated -$0.17 by +47.06%, while revenue for the quarter reached $4.72k .
Earnings released on 14 Nov 2023
EPS came in at -$0.19 surpassing the estimated -$0.33 by +42.42%.
Earnings released on 14 Aug 2023
EPS came in at -$0.27 .
Earnings released on 15 May 2023
EPS came in at -$0.58 .
Earnings released on 8 Mar 2023
EPS came in at -$0.90 , while revenue for the quarter reached -$3.11k .
Earnings released on 14 Nov 2022
EPS came in at -$0.85 .
Earnings released on 12 Aug 2022
EPS came in at -$0.38 .
Stock split effective on 28 Jun 2022
Shares were split 1 : 60 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 13 May 2022
EPS came in at -$0.60 , while revenue for the quarter reached $2.67k .
Earnings released on 31 Dec 2021
EPS came in at -$0.30 , while revenue for the quarter reached $3.25k .
Earnings released on 12 Nov 2021
EPS came in at -$0.16 , while revenue for the quarter reached $3.15k .
Earnings released on 12 Aug 2021
EPS came in at -$0.04 .
PMN Stock Performance
Access detailed PMN performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
